Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 8/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 7/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.35 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985204 | 1.00 | SCN10A (0.40) | SCN10AMAP4K4SCN2ABRD4CCNC | |
| SCHEMBL11985268 | 0.91 | MKNK1 (0.34) | SCN10AMAP4K4MKNK1MKNK2XDH | |
| SCHEMBL870934 | 0.90 | XDH (0.45) | MAP4K4MKNK1MKNK2XDH | |
| SCHEMBL871636 | 0.90 | KAT6A (0.40) | SCN10ASCN2ABRD4CCNCCDK8 | |
| SCHEMBL11985203 | 0.90 | KAT6A (0.40) | SCN10ASCN2ABRD4CCNCCDK8 | |
| SCHEMBL869138 | 0.85 | XDH (0.35) | MKNK1MKNK2XDH | |
| SCHEMBL10182185 | 0.84 | KMO (0.41) | MAP4K4MKNK1MKNK2XDH | |
| SCHEMBL869367 | 0.84 | XDH (0.49) | MKNK1MKNK2XDH | |
| SCHEMBL10182211 | 0.82 | SCN10A (0.47) | SCN10ACCNCCDK8 | |
| SCHEMBL868338 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383825-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8143410-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110263611-A1 | Kinase Inhibitors | ALLERGAN, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263611-A1 | Kinase Inhibitors | PTK2, MAP3K6, MAP3K20 | SCN10A 4600/4885MAP4K4 62/4885SCN2A 4482/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | SCN10A 4600/4885MAP4K4 62/4885SCN2A 4482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.